Stock Region Penny Picks
Stock Region Penny Picks Watchlist Newsletter: Monday, November 17, 2025
Stock Region Penny Picks Watchlist Newsletter: Monday, November 17, 2025
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: Good morning, everyone! Before we dive in, please remember that this newsletter is for informational and entertainment purposes only. The content here represents my personal opinions and observations. It is not financial advice. Always do your own research and consult with a qualified financial professional before making any investment decisions. Trading stocks involves risk, and you could lose your investment.
What a day it was yesterday! The market was buzzing with activity, and we saw some truly impressive moves. I’ve been digging through the news and charts to bring you what I believe are the most interesting tickers to keep an eye on. Let’s get right into the breakdown of what caught my attention.
Today’s Top Watchlist
$BRTX - BioRestorative Therapies
This one kicked off the morning with a bang. They announced a Type B meeting with the FDA to discuss an accelerated approval pathway for their chronic back pain treatment, BRTX-100. The word “accelerated” is music to my ears when it comes to biotech. It signals confidence and could potentially shorten the timeline to market. This is a huge step forward for them and definitely puts $BRTX on my radar for any follow-up news.
$SUUN - Sunergy Renewables
From pain relief to profit, $SUUN delivered a fantastic earnings report. They’re back to profitability with a 106% year-over-year gross profit jump and a 145% increase in adjusted EBITDA. That’s not just growth; that’s an explosion. This kind of turnaround story is exactly what I love to see. It shows strong management and market demand.
$LFWD - Lifeward, Inc.
Here’s a story that feels good. UnitedHealthcare approved prior authorization for a ReWalk 7 Personal Exoskeleton. This isn’t just a sale; it’s a major validation from a healthcare giant. It opens the door for more approvals and wider adoption. It’s a powerful catalyst that shows their technology is gaining real-world traction.
$LFMD - LifeMD, Inc.
Weight-loss drugs are a hot topic, and LifeMD is jumping right into the center of it. They’re now offering top-tier pricing for Wegovy® and Ozempic® through their partnership with Novo Nordisk. By making these popular medications more accessible, they are tapping into a massive, high-demand market. This is a savvy business move that could significantly boost their customer base and revenue.
$CPOP - POP Culture Group
Saving one of the biggest for last! $CPOP reported absolutely stellar results after the bell. They smashed the $100 million revenue mark for the first time, with a massive 127% year-on-year surge. This kind of hyper-growth is rare and demands attention. The numbers speak for themselves, and I’ll be watching to see if this momentum can continue.
High-Volume Movers
We also saw some serious volume spikes yesterday that are worth noting. These tickers were lighting up the scanners, indicating high interest and potential volatility. Keep them on your screen:
$CGTL: Saw a nice pop to $0.97 on heavy volume.
$ONEG: Pushed up to $2.30 with a significant increase in trading activity.
$UONEK: Another one that caught a bid, spiking to $0.8083.
$ANVS: A big surge to $3.32 had this one on everyone’s radar.
$APLT: Showed signs of life with a volume spike to $0.3386.
That’s a wrap for today’s main watchlist! It was a day filled with powerful catalysts and impressive earnings. As always, trade smart, manage your risk, and be ready for opportunities. I’ll be right here watching the markets with you.
Happy trading!
Final Disclaimer: All information contained in this newsletter is based on my personal opinion and analysis. It is not a recommendation to buy or sell any securities. Investing in the stock market carries risks, and you are solely responsible for your own investment decisions. Please conduct your own due diligence.